U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N16O12.CH4O3S
Molecular Weight 1305.504
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEUPROLIDE MESYLATE

SMILES

CS(O)(=O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6

InChI

InChIKey=MBIDSOMXPLCOHS-XNHQSDQCSA-N
InChI=1S/C59H84N16O12.CH4O3S/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-5(2,3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,2,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/ppa/leuprolide.html | http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020011s040lbl.pdf | http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf

Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. It acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. Leuprolide acetate used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, uterine leiomyomata (fibroids), endometriosis and precocious puberty.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LUPRON

Approved Use

LEUPROLIDE ACETATE INJECTION is indicated in the palliative treatment of advanced prostatic cancer.

Launch Date

1985
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
32.48 ng/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
426.2 ng × h/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
54%
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Other AEs: Asthenia, General body pain...
Other AEs:
Asthenia (6 patients)
General body pain (16 patients)
Headache (5 patients)
Injection site reaction (4 patients)
Hot flashes (23 patients)
Gastrointestinal disorder (NOS) (5 patients)
Dehydration (4 patients)
Edema (4 patients)
Disorder joint (8 patients)
Myalgia (4 patients)
Vertigo (3 patients)
Neuromuscular disorders (3 patients)
Paresthesia (4 patients)
Skin reaction (6 patients)
Urinary tract disorder NOS (5 patients)
Sources:
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Other AEs: General body pain, Hot flashes...
Other AEs:
General body pain (13 patients)
Hot flashes (32 patients)
Gastrointestinal disorder (NOS) (8 patients)
Edema (8 patients)
Libido decreased (3 patients)
Disorder urinary tract (7 patients)
Impotence (3 patients)
Atrophy testicular (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
General body pain 16 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Hot flashes 23 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Neuromuscular disorders 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Vertigo 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Dehydration 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Edema 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Injection site reaction 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Myalgia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Paresthesia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Gastrointestinal disorder (NOS) 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Headache 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Urinary tract disorder NOS 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Asthenia 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Skin reaction 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
Disorder joint 8 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 49
Sources:
General body pain 13 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Atrophy testicular 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Impotence 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Libido decreased 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Hot flashes 32 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Disorder urinary tract 7 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Edema 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
Gastrointestinal disorder (NOS) 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
n = 56
Health Status: unhealthy
Condition: cancer
Age Group: adult
Sex: unknown
Population Size: 56
Sources:
PubMed

PubMed

TitleDatePubMed
Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.
1991 Sep-Oct
Adverse effects of leuprolide acetate depot treatment.
1993 Feb
Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism.
1993 Jan
Angina and myocardial infarction with use of leuprolide acetate.
1994 Jul
Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
1996 Jan
Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
1997 Oct
Steroidal 'add-back' therapy in patients treated with GnRH agonists.
1998
Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy.
1998 Mar 15
Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy.
1999 Jan
Lupron-induced mania.
1999 Jan 15
Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.
1999 Mar
Uterine adenocarcinoma after GnRH agonist treatment.
2000 Feb
Pituitary haemorrhage after leuprolide therapy for prostatic cancer, clinically imitating acute subarachnoidal haemorrhage.
2002
Leuprolide-induced myopathy.
2002 Oct
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
2002 Sep
Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
2003 Mar-Apr
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
2004 May
Leuprolide acetate suppresses pedophilic urges and arousability.
2005 Dec
Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells.
2005 May
A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders.
2006 Dec
Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
2006 Jan
Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.
2007 Feb
Leuprolide acetate and central retinal vein occlusion.
2007 Nov-Dec
Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
2007 Oct
Nonalcoholic fatty liver disease induced by leuprorelin acetate.
2008 Jan
Tricuspid valve thrombus: a case report associated with gonadotropin-releasing hormone analogue therapy and review of the literature.
2008 May
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
2008 May 15
A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
2009 Jun
Long-term effects of GnRH agonist, GnRH antagonist, and estrogen plus progesterone treatment on apoptosis related genes in rat ovary.
2009 May
Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
2010
Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study.
2010 Dec
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.
2011 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Dosing: Adult Prostate cancer, advanced: Note: Treatment is usually continued after development of metastatic (castration-resistant) disease. IM: Lupron Depot 7.5 mg (monthly): 7.5 mg every month or Lupron Depot 22.5 mg (3 month): 22.5 mg every 12 weeks or Lupron Depot 30 mg (4 month): 30 mg every 16 weeks or Lupron Depot 45 mg (6 month): 45 mg every 24 weeks SubQ: Eligard: 7.5 mg monthly or 22.5 mg every 3 months or 30 mg every 4 months or 45 mg every 6 months Leuprolide acetate 5 mg/mL solution: 1 mg daily Endometriosis: IM: Initial therapy may be with leuprolide alone or in combination with norethindrone; if re-treatment for an additional 6 months is necessary, concomitant norethindrone should be used. Re-treatment is not recommended for longer than one additional 6-month course. Lupron Depot: 3.75 mg every month for up to 6 months or Lupron Depot-3 month: 11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment) Uterine leiomyomata (fibroids): IM (in combination with iron): Lupron Depot: 3.75 mg every month for up to 3 months or Lupron Depot-3 month: 11.25 mg as a single injection Breast cancer, premenopausal ovarian supression (off-label use): IM: Lupron Depot: 3.75 mg every 28 days for up to 24 months (Boccardo 1999) or Lupron Depot-3 month: 11.25 mg every 3 months for up to 24 months (Boccardo 1999; Schmid 2007) Treatment of paraphilia/hypersexuality (off-label use; Guay 2009; Reilly 2000): Males: IM: Note: May cause an initial increase in androgen concentrations which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1 to 2 months (Guay 2009). Avoid use in patients with osteoporosis or active pituitary pathology. SubQ: Test dose: 1 mg (observe for hypersensitivity) Depot IM: 3.75 to 7.5 mg monthly Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males): IM: Lupron Depot-Ped (monthly): ≤25 kg: 7.5 mg every month >25 to 37.5 kg: 11.25 mg every month >37.5 kg: 15 mg every month Titrate dose upward in increments of 3.75 mg every 4 weeks if down-regulation is not achieved. Lupron Depot-Ped (3 month): 11.25 mg or 30 mg every 12 weeks SubQ (leuprolide acetate 5 mg/mL solution): Initial: 50 mcg/kg/day; titrate dose upward by 10 mcg/kg/day if down-regulation is not achieved. Note: Higher mg/kg doses may be required in younger children.
Route of Administration: Other
In primary cell cultures from human prostate carcinoma leuprolide (from 5-20 ng/mL) showed a significant reduction in cell growth rate and an increase in DNA-fragmented cell number.
Name Type Language
LEUPROLIDE MESYLATE
Common Name English
Leuprorelin mesilate [WHO-DD]
Common Name English
CAMCEVI
Brand Name English
PGLU-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHC2H5 METHANESULFONATE
Common Name English
PGLU-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHC2H5 MESYLATE
Common Name English
LEUPRORELIN MESYLATE
Common Name English
LEUPRORELIN MESILATE
Common Name English
1-9-LUTEINIZING HORMONE-RELEASING FACTOR (SWINE), 6-D-LEUCINE-9-(N-ETHYL-L-PROLINAMIDE)-, METHANESULFONATE (1:1)
Common Name English
LEUPROLIDE MESYLATE [ORANGE BOOK]
Common Name English
Code System Code Type Description
DAILYMED
8E3C3C493W
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
FDA UNII
8E3C3C493W
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
SMS_ID
300000042564
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
CAS
944347-41-5
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID30241484
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
NCI_THESAURUS
C190727
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
RXCUI
2595041
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
PUBCHEM
73456806
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY
EVMPD
SUB179052
Created by admin on Sat Dec 16 19:03:47 GMT 2023 , Edited by admin on Sat Dec 16 19:03:47 GMT 2023
PRIMARY